Where are Boston Scientific Corporation on Map
Get Directions
| Title | Category | Description | Link | Address | Phone Number | Type |
|---|
Boston Scientific Corporation is a globally recognized medical technology company specializing in the development, manufacturing, and marketing of medical devices used in interventional medical specialties. Founded in 1979, the company has played a pioneering role in advancing less invasive medical solutions that improve patient care and outcomes.
Boston Scientific operates in multiple therapeutic areas, including cardiology, urology, neuromodulation, endoscopy, and peripheral interventions. Its innovative products help physicians diagnose and treat a wide range of medical conditions, making it a leader in the healthcare sector. With a commitment to research and development, the company continuously expands its portfolio by investing in cutting-edge technology and acquiring businesses that align with its mission.
Boston Scientific Corporation Headquarters Address
| Traded as | (BSX Stock) NYSE: BSX |
| ISIN | US1011371077 |
| Industry focused | Medical devices industry |
| Founded in | 1979 |
| Founder | John Abele, Founder & Director Emeritus; Peter Nicholas, Founder & Director Emeritus |
| Headquarters/Based in | Marlborough, Massachusetts, USA |
| Products | Branded medical devices |
Contact
- Mailing address: 300 Boston Scientific Way, Marlborough, MA 01752, USA
- Boston Scientific Japan: Nikko Building,1-14-11 Nishi Shinjuku, Shinjuku-ku, Tokyo, Â 160-0023, Japan
- Phone number: 508-683-4000
- Website: www.bostonscientific.com
Subsidiaries
- Guidant
- Cameron Health
- Symetis SA
- Target Therapeutics Inc.
- Cardiac Pacemakers, Inc.
Key People/Executives for Boston Scientific Corporation
| Mr. Michael F. Mahoney | Chief Exec. Officer, Pres and Director |
| Mr. Daniel J. Brennan | Chief Financial Officer and Exec. VP |
| Mr. Timothy A. Pratt | Chief Admin. Officer, Exec. VP, Gen. Counsel and Sec |
| Mr. Joseph M. Fitzgerald | Exec. VP and Pres of Rhythm Management |
| Mr. Kevin J. Ballinger | Exec. VP and Pres of Interventional Cardiology |
Boston Scientific Corporation Profile/Overview
- Forming of the BSC was done on June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine. IPO was made by the company on May 19, 1992.
Approval to The Taxus Stent was made in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was considered as the second drug-eluting stent approved in the USA. - On April 21, 2006, the company made an acquisition to their longtime competitor Guidant for $27.2 billion. It was then split between BSC and Abbott Laboratories.
- Forming of Navilyst Medical was done in February 2008 from Boston Scientific’s Fluid Management and Vascular Access business units.
Boston Scientific Corporation Products/Capabilities
Boston Scientific Corporation is highly dedicated in developing, manufacturing, and marketing medical devices for use in various interventional medical specialties internationally. It operates through three segments:
- Cardiovascular
- Rhythm Management
- MedSurg
The company offers the following products:
- Interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease
- Other coronary therapy products to treat atherosclerosis
- Intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels
- Structural heart therapy systems
- Stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease
- Biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors.
- Cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms
- Implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure
- Medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories
- Products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions
- Devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs
- Products to treat urinary stone disease and benign prostatic hyperplasia
- Mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices
- And spinal cord stimulator systems for the management of chronic pain
Conclusion
Boston Scientific Corporation went public through an Initial Public Offering (IPO) on May 19, 1992. The company’s stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol BSX.
Boston Scientific Corporation is a leading medical technology company with a global footprint. The company has remained a strong player in the stock market, attracting investors through its continuous advancements and commitment to excellence in healthcare.
As the demand for minimally invasive medical treatments grows, Boston Scientific is well-positioned to remain at the forefront of the industry.
